136 related articles for article (PubMed ID: 6432833)
1. Interpretive criteria and tentative quality control limits for apalcillin disk susceptibility tests.
Barry AL; Thornsberry C; Jones RN; Gavan TL
J Clin Microbiol; 1984 Jun; 19(6):777-82. PubMed ID: 6432833
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of apalcillin and piperacillin against gram-negative bacilli.
Fass RJ; Helsel VL
Antimicrob Agents Chemother; 1984 Nov; 26(5):660-4. PubMed ID: 6440476
[TBL] [Abstract][Full Text] [Related]
3. Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.
Barry AL; Jones RN; Thornsberry C
J Clin Microbiol; 1984 Feb; 19(2):134-9. PubMed ID: 6321543
[TBL] [Abstract][Full Text] [Related]
4. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.
Barry AL; Jones RN
J Clin Microbiol; 1988 Apr; 26(4):750-4. PubMed ID: 3130390
[TBL] [Abstract][Full Text] [Related]
5. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
[TBL] [Abstract][Full Text] [Related]
6. Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group.
Barry AL; Jones RN
J Clin Microbiol; 1990 Mar; 28(3):605-7. PubMed ID: 2182675
[TBL] [Abstract][Full Text] [Related]
7. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Zerva L; Biedenbach DJ; Jones RN
J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
[TBL] [Abstract][Full Text] [Related]
8. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.
Barry AL; Thornsberry C; Gavan TL
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):544-9. PubMed ID: 2548865
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers.
Barry AL; Jones RN; Ayers LW; Gavan TL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1984 May; 25(5):669-71. PubMed ID: 6732234
[TBL] [Abstract][Full Text] [Related]
10. Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.
Jones RN; Gavan TL; Barry AL; Thornsberry C; Gibbs DL
J Clin Microbiol; 1982 May; 15(5):777-86. PubMed ID: 6212596
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests.
Barry AL; Fuchs PC; Jorgensen JH; Tenover FC; Allen SD; Hardy DJ; McLaughlin JC
J Clin Microbiol; 1993 Mar; 31(3):751-3. PubMed ID: 8384632
[TBL] [Abstract][Full Text] [Related]
12. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
Jones RN; Sutton LD; Cantrell HF; Lankford RB
Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
[TBL] [Abstract][Full Text] [Related]
13. Interpretive standards and quality control guidelines for cefpiramide disk susceptibility tests.
Barry AL; Gavan TL; Thornsberry C; Jones RN
J Clin Microbiol; 1985 Oct; 22(4):688-90. PubMed ID: 4077974
[TBL] [Abstract][Full Text] [Related]
14. Interpretive standards and quality control guidelines for imipenem susceptibility tests with 10-micrograms disks.
Barry AL; Thornsberry C; Gavan TL; Jones RN
J Clin Microbiol; 1984 Nov; 20(5):988-9. PubMed ID: 6439736
[TBL] [Abstract][Full Text] [Related]
15. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.
Barry AL; Thornsberry C; Jones RN; Gavan TL
Rev Infect Dis; 1985; 7 Suppl 4():S594-604. PubMed ID: 3909316
[TBL] [Abstract][Full Text] [Related]
16. Activity of apalcillin against Pseudomonas aeruginosa.
Hollick GE; Gundrum J; Venezia RA
Antimicrob Agents Chemother; 1984 Sep; 26(3):408-9. PubMed ID: 6439115
[TBL] [Abstract][Full Text] [Related]
17. Apalcillin [PC-904]: spectrum of activity and beta-lactamase hydrolysis/inhibition.
Barry AL; Jones RN; Thornsberry C
Diagn Microbiol Infect Dis; 1985 Jan; 3(1):7-17. PubMed ID: 3871382
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1982 Jun; 21(6):906-11. PubMed ID: 6981375
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.
Barry AL; Fass RJ; Anhalt JP; Neu HC; Thornsberry C; Tilton RC; Painter BG; Washington JA
J Clin Microbiol; 1985 Jun; 21(6):880-3. PubMed ID: 3159749
[TBL] [Abstract][Full Text] [Related]
20. Interpretive criteria for temocillin disk diffusion susceptibility testing.
Fuchs PC; Barry AL; Thornsberry C; Jones RN
Eur J Clin Microbiol; 1985 Feb; 4(1):30-3. PubMed ID: 3872793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
